Sanofi vaccine sales down in the fourth quarter but up over the year | Poconos and Coal Region

PARIS – So far, the 2021-2022 flu season has been rather mild. Good news for the man but not so good news for Sanofi, the parent company of Sanofi Pasteur headquartered in Swiftwater, Pa., which saw fourth-quarter vaccine sales drop 6.5% despite strong European sales.

On the bright side, for the whole of 2021, Sanofi’s vaccine sales were up 6.8% from 2020.

The United States was the main culprit for the drop in vaccine sales in the fourth quarter due to an emphasis on Covid-19 booster shots at pharmacies in the country.

For all of Sanofi, the fourth quarter and full year 2021 saw an increase in sales and earnings per share (EPS), although earnings showed a sharp decline of 49.3% due to an adjustment accounting related to the treatment of capital gains from the sale of its shares. from pharmaceutical company Regeneron in 2020.

Sanofi recorded several milestones in the fourth quarter. On November 9, the company announced the completion of its acquisition of Kadmon Holdings, Inc., further strengthening the general drug portfolio.

On November 18, Sanofi announced a capital investment of $180 million and a new strategic collaboration with Owkin, an artificial intelligence and precision medicine company, aimed at optimizing clinical trial design and detecting predictive biomarkers for disease and treatment outcomes in key areas such as lung cancer. , breast cancer and multiple myeloma.

On December 1, Sanofi announced the acquisition of Origimm Biotechnology GmbH, a biotechnology company specializing in the discovery of virulent components of the skin microbiome and antigens of bacteria responsible for skin diseases.

On December 21, Sanofi announced that it had entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company, to leverage its proprietary XTEN technology and innovative protease-releasing masking technology platform , ProXTENTM, to discover and develop T-cell engages (TCE) and cytokine-based therapies for cancer patients.

In a statement, Sanofi Chief Executive Officer Paul Hudson said, “Sanofi closed 2021 with a strong fourth quarter performance, driven by double-digit sales growth from Dupixent, which continues to establish impressive record sales quarter after quarter. This quarter marks the first time that Specialty Care has led our GBUs (Global Business Units) in terms of sales, marking an important milestone in our transformation. At the same time, Vaccines achieved another year of record flu sales and is on a clear growth trajectory, as demonstrated by our recent Vaccine Day.

Fourth Quarter and Full Year 2021 Operating Results

In the fourth quarter of 2021, Sanofi’s sales amounted to 9.994 billion euros, up 6.5% as reported. Changes in exchange rates had a positive effect of 2.4%, mainly due to the US dollar. At constant exchange rates, the company’s turnover increased by 4.1%. In 2021, Sanofi’s sales reached 37.761 billion euros, up 4.8% on a reported basis. Changes in exchange rates had a negative effect of 2.3%. At CER, company sales increased 7.1%.

Fourth-quarter business operating income (BOI) increased 9.9% to 2.256 billion euros. At TCC, the BOI increased by 6.9%.

In the fourth quarter, sales in the United States increased by 1.8% to €3.820 billion, supported by the solid performance of Dupixent® and the double-digit growth of Consumer Healthcare, Diabetes and Oncology. For the full year of 2021, sales in the United States increased by 10.3%.

In Europe, sales increased by 9.8% in the fourth quarter to 2.804 billion euros, mainly thanks to the performance of Dupixent® as well as the strong growth of Vaccines. In 2021, European sales increased by 6.6% thanks to the growth of specialty medicine products as well as the good performance of vaccines.

In the Rest of the World, sales increased by 2.3% to 3.370 billion euros in the fourth quarter. Sales in China increased by 5.7% to 558 million euros mainly due to the growth of Dupixent, Plavix and Vaccines. In Japan, fourth-quarter sales increased 0.5% to €404 million, driven by Dupixent and Sarclisa. In the Rest of the World, 2021 sales increased by 4.4%.

Vaccines Results

Fourth-quarter Vaccines sales decreased 6.5% to €1,964 million, primarily reflecting lower influenza vaccine sales in the United States, partially offset by the successful expansion of Efluelda® in Europe and Polio/Pertussis/Hib in the Rest of the World region. In 2021, vaccine sales increased by 6.8%, supported by meningitis, influenza and PPH vaccines.

In the fourth quarter, sales of Polio/Pertussis/Hib (PPH) vaccines increased by 7.7% to €543 million, driven by Pentaxim® in China and Hexaxim® in Europe. In the United States, sales of Pentacel® decreased due to fluctuating inventories and the gradual ramp-up of Vaxelis®. Sales of flu vaccines fell 12.4% in the fourth quarter to 1.093 billion euros. In the United States, fourth-quarter influenza vaccine sales were down 48.3%, reflecting lower influenza vaccination rates compared to a year ago, which resulted from the prioritization of COVID-19 booster vaccinations. 19 at the pharmacy level, as well as record shipments in the third quarter of 2021.

In Europe, sales of influenza vaccines increased by 51.1% thanks to the adoption of a preferential recommendation of Efluelda® for people over 60 in Germany. In the Rest of the World region, influenza sales increased by 22.7%.

On a full-year basis, Sanofi says 2021 marked another record year with flu vaccine sales up 5.9% to 2.628 billion euros. In the fourth quarter, sales of meningitis decreased by 31.2% to 91 million euros. Booster vaccines sales decreased 1.6% in the fourth quarter to €124 million, due to lower sales in the Rest of the World region partially offset by growth in Europe.

In the fourth quarter, sales of travel and endemic vaccines increased by 17.1%, reflecting a weak comparison base in the fourth quarter of 2020 due to the pandemic environment.

In the fourth quarter, business operating profit (BOI) decreased by 22.3% to 653 million euros compared to the same period last year. This reflects lower flu vaccine sales in the United States and increased R&D spending related to Translate Bio which Sanofi is in the process of acquiring and the mRNA Center of Excellence through which Sanofi intends advancing mRNA technology research. For the full year 2021, the BOI increased by 11.7% to €2.609 billion, benefiting from the sales performance and an efficiency gain as well as a payment from Daiichi Sankyo to the first quarter of 2021.

Results of other business segments

In the fourth quarter of 2021, Pharmaceuticals sales increased by 7.4% to 6.919 billion euros, mainly driven by the Specialty Care portfolio, up 21.3%, with the continued good performance of Dupixent ® while General Medicine sales fell by 3.8%. In 2021, Pharmaceuticals sales increased 7.6% to €26.970 billion, reflecting the strong performance of specialty and general medicine core assets.

In the fourth quarter, operating profit from Pharmaceuticals activities increased by 16.4% to €2.091 billion In 2021, operating profit from Pharmaceuticals activities increased by 2.2% to €9.409 million euros.

In the fourth quarter, Consumer Healthcare (CHC) sales increased 5.6% to €1.111 billion, driven by growth in the United States and Europe. This performance was driven by the Cough and Cold franchise, as well as the Bread Care category which benefited from COVID-19 vaccinations. In 2021, CHC sales increased by 4.6%, primarily due to sales growth in the digestive wellness, pain care and mental wellness categories, which more than offset a weak cough and cold season last winter and divestments of non-essential products.

In the fourth quarter, CHC’s business operating profit (BOI) decreased by 2.0% to 298 million euros. In 2021, BOI for Consumer Healthcare increased by 5.9% to €1.493 billion due to higher sales, contained operating expenses and higher capital gains from disposals non-strategic assets.

Research and Development Highlights

“In R&D,” Hudson commented, “we continue to be relentless in our commitment to expanding our innovative pipeline. seven pipeline programs in phase 2 trials, demonstrating our success in rapidly advancing potentially transformative drugs.

“We have further strengthened our R&D capabilities with a series of value-creating M&A transactions in 2021. Our strong financial performance validates our ability to increase profitability through an enhanced product mix, supported by expense management and the reinvestment of savings in our engines of growth, all of which puts us on the path to achieving our 2022 financial objectives.“

Financial outlook 2022

Sanofi said it expects 2022 business EPS to see low double-digit growth at CER barring unforeseen major adverse events. By applying the average exchange rates of January 2022, the positive exchange rate effect on the EPS of the 2022 activities is estimated between +2% and +3%.

Sanofi SA (NYSE: SNY) is a multinational pharmaceutical company headquartered in Gentilly, France. It has more than 100,000 employees in 100 countries around the world with 81 manufacturing sites in 36 countries. Sanofi Pasteur, the vaccines division of Sanofi, is headquartered in Swiftwater, Pennsylvania, in Monroe County.

Comments are closed.